NCT06280508 Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
| NCT ID | NCT06280508 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Condition | Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2024-03-01 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
Eligibility Criteria
Inclusion Criteria: * confirmed intrahepatic cholangiocarcinoma * with Resectable tumor lesion * no contraindications to surgery * with high risk of tumour recurrence * No prior systemic therapy for intrahepatic cholangiocarcinoma. * ECOG Performance Status of 0 or 1 * Child-Pugh Class: Grade A Exclusion Criteria: * History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage * Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * Known genetic or acquired hemorrhage or thrombotic tendency * Thrombosis or thromboembolic event within 6 months prior to the start of study treatment * Cardiac clinical symptom or disease that is not well controlled * Hypertension that can not be well controlled through antihypertensive drugs
Contact & Investigator
Yajin Chen
STUDY DIRECTOR
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Frequently Asked Questions
Who can join the NCT06280508 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06280508 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06280508 currently recruiting?
Yes, NCT06280508 is actively recruiting participants. Contact the research team at cyj0509@126.com for enrollment information.
Where is the NCT06280508 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06280508 clinical trial?
NCT06280508 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The principal investigator is Yajin Chen at Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The trial plans to enroll 40 participants.